<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321267</url>
  </required_header>
  <id_info>
    <org_study_id>H26-035</org_study_id>
    <nct_id>NCT02321267</nct_id>
  </id_info>
  <brief_title>Cohort Study of the Clinical Course of Macular Diseases in Kagawa</brief_title>
  <official_title>Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kagawa University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kagawa University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Macular diseases often cases severe visual impairment. Recent clinical introduction of
      anti-vascular endothelial growth factor agents may change the clinical course of various
      macular diseases, including age-related macular degeneration (AMD), polypoidal choroidal
      vasculopathy (PCV), retinal angiomatous proliferation (RAP), central serous chorioretinopathy
      (CSC), myopic choroidal neovascularization (CNV), retinal vein occlusion (RVO), diabetic
      macular edema (DME), and so forth. The advance in vitrectomy improve visual outcomes in some
      maculae diseases, including epiretinal membrane (ERM), macular hole (MH), vitreomacular
      traction syndrome (VMTS).

      Patients with such macular diseases are registered and are followed up for 5 years with
      appropriate treatment for each patient. By the analysis of the correlation between initial
      examinations and final visual acuity, factors associated with good visual prognosis will be
      elucidated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of best-collected visual acuity from baseline at 5 years</measure>
    <time_frame>Five years after the registration</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Macular Disease</condition>
  <arm_group>
    <arm_group_label>Macular disease with adequate treatments</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Macular diseases can be treated with most appropriate treatment, including pegaptanib, ranibizumab, afibercept, visudyne, or vitrectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab, aflibercept, pegaptanib, verteporphin</intervention_name>
    <description>ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/„é°</description>
    <arm_group_label>Macular disease with adequate treatments</arm_group_label>
    <other_name>Lucentis, Eylea, Macugen, Vizudyne</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who visit Department of Ophthalmology, Kagawa University Hospital with
             macular diseases, such as AMD, PCV, RAP, RVO, DME, ERM, MH, VMTS.

          -  Patients who are agreed with the participation of this study.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Akiataka Tsujikawa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kagawa Univerisity Faculty of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chika Akuta</last_name>
    <phone>+81-87-891-2211</phone>
    <email>kaomie@med.kagawa-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kagawa University Faculty of Medicine</name>
      <address>
        <city>Miki</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+81878912211</phone>
      <email>chosa@med.kagawa-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2014</study_first_submitted>
  <study_first_submitted_qc>December 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kagawa University</investigator_affiliation>
    <investigator_full_name>Akitaka Tsujikawa</investigator_full_name>
    <investigator_title>Professor and Chairman</investigator_title>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>PCV</keyword>
  <keyword>RAP</keyword>
  <keyword>RVO</keyword>
  <keyword>DME</keyword>
  <keyword>ERM</keyword>
  <keyword>MH</keyword>
  <keyword>mCNV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

